[1]Scheuer JP.Classification of chronic viral hepatitis:a need for reas-sessment[J].Journal of Hepatology, 1991, 13∶372-374.
|
[2]Pinzani M, Marra F.Cytokine receptors and signaling in hepatic stel-late cells[J].Semin Liver Dis, 2001, 21∶397-416.
|
[3]Serviddio G, Pereda J, Pallardo FV, et al.Ursodeoxycholic acidprotects against secondary biliary cirrhosis in rats by preventing mito-chondrial oxidative stress[J].Hepatology, 2004, 39∶711-20.
|
[4]Nava-Ocampo AA, Suster S, Muriel P.Effect of colchiceine andursodeoxycholic acid on hepatocyte and erythrocyte membranes andliver histology in experimentally induced carbon tetrachloride cirrhosisin rats[J].Eur J Clin Invest, 1997, 27∶77-84.
|
[5]Weitzel C, Stark D, Kullmann F, et al.Ursodeoxycholic acid in-duced activation of the glucocorticoid receptor in primary rat hepato-cytes[J].Eur J Gstroenterol Hepatol, 2005, 17∶169-177.
|
[6]陈治新, 陈运新, 翁山耕, 等.PDGF-BB对肝星状细胞表达MMP-2及TIMP-1的影响[J].胃肠病学和肝病学杂志, 2003, 12∶46-48.
|
[7]楼颂梅, 王开明, 蔡卫民, 等.慢性乙型肝炎肝组织血小板衍生生长因子的表达及意义[J].中华肝脏病杂志, 2003, 11∶49-51.
|
[8]段志军, 胡祥.免疫性肝纤维化中肝组织基质金属蛋白酶-1及其抑制因子-1的表达[J].中华消化杂志, 2002, 22∶566-567.
|
[9]Peterson TC, Slysz G, Isbrucker R.The inhibitory effect of ursode-oxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP[J].Immunopharmacology, 1998, 39∶181-191.
|
[1] | Nan WANG, Rong HU, Shihui BIAN, Wei ZHONG, Pengfei ZHANG, Youwen TAN. Value of alkaline phosphatase level after ursodeoxycholic acid treatment for one month and baseline red blood cell distribution width in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 496-501. doi: 10.12449/JCH240310 |
[2] | Xinyu CUI, Yanyan LI, Na ZHU, Yingying LIN, Xin LI. Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(3): 489-495. doi: 10.12449/JCH240309 |
[3] | Zhang YuGuo, Zhao SuXian, Li WenCong, Ren WeiGuang, Nan YueMin. Clinical effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1322-1325. doi: 10.3969/j.issn.1001-5256.2019.06.028 |
[4] | Ding Jie, Wang Liang, Li Juan, Kong Yin, Zhao Rui, He JingJing, Li GuangMing, Wang JuanXia, Zhang LingYi. Changes in serum asymmetric dimethylarginine levels in progression of liver inflammation in an experimental rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(1): 148-151. doi: 10.3969/j.issn.1001-5256.2016.01.029 |
[5] | Zhu JinZhao, Rao JunWei, Lu: Yong, Li Huan. Changes in distribution of cholinergic and nitrergic nerves in antrum of rats with liver failure[J]. Journal of Clinical Hepatology, 2014, 30(10): 1023-1026. doi: 10.3969/j.issn.1001-5256.2014.10.012 |
[6] | Wang WeiZhen, Meng MingHui, Kong Li, Zhang QingShan, Zhao SuXian, Nan YueMin. Role of Jak /Stat pathway in CCl4- induced rat liver fibrosis model and molecular action mechanism of Fuzheng Huayu recipe in treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 344-348. doi: 10.3969/j.issn.1001-5256.2014.04.014 |
[7] | Hu XingWu, Qi ChangJin, Zhou HongXing. Therapeutic efficacy of ursodeoxycholic acid for drug-induced liver disease[J]. Journal of Clinical Hepatology, 2012, 28(9): 695-696. |
[8] | Nong XiTing, Huang Hua, Qin Rong, Lu MingLiang. The Changes in substance P in jejunum of fatty liver[J]. Journal of Clinical Hepatology, 2010, 26(1): 33-35. |
[9] | Song MinNing, Chen Fu, Song YuNa, Xie ZeJin. The influence of 5-hydroxytryptamine on rat with hepatic encephalopathy.[J]. Journal of Clinical Hepatology, 2008, 24(2): 88-91. |
[10] | Gao Feng, Zhang FuKui, Jia JiDong. Liver function changes of ursodeoxycholic acid made in china for patients with primary biliary cirrhosis.[J]. Journal of Clinical Hepatology, 2008, 24(4): 278-280. |
[11] | Xing LingXiang, He YongWen. Experiment study on nonalcoholic fatty liver model induced by injection of oxytetracycline intraperitoneally in rats[J]. Journal of Clinical Hepatology, 2007, 23(1): 29-31. |
[14] | Tan YouWen, Wu JianCheng, Wu XueJun. Efficacy of ursodeoxycholic acid in the treatment of type Ⅰ autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(5): 283-284. |
[16] | Chu YanJun, Lu YanRu. Effects of spirulina in prevention of liver fibrosis in rats[J]. Journal of Clinical Hepatology, 2003, 19(6): 372-373. |
[17] | Shen FengJun, Yin ChengHong, Ma Hong, Ma XueMei, Jia JiDong, Wang BaoEn, Zhu YueKe, Liu TianHui. Expression of angiotensin Ⅱ type 1 receptors mRNA in rat experimental biliary fibrosis[J]. Journal of Clinical Hepatology, 2002, 18(5): 279-281. |
[18] | Yin ChengHong, Ma Hong, Ma XueMei, Liu TianHui, Jia JiDong, Wang BaoEn. The effect of compound 861 on MMP2mRNA expression in liver fibrosis induced by bile Duct occlusion in rats[J]. Journal of Clinical Hepatology, 2002, 18(4): 248-250. |